Skip to Main Content

Advertisement

MIT Press Direct, home
header search
Search
Advanced Search
Skip Nav Destination

Pharmaceutical Price Controls and Entry Strategies

The Review of Economics and Statistics (2007) 89 (1): 88–99.
This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.
Healthcare Payer Perspectives on the Assessment and Pricing of Oncology Multi-Indication Products: Evidence from Nine OECD Countries
  • Mackenzie Mills
  • Panos Kanavos
PharmacoEconomics - Open (2023) 7 (4): 553.
The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets
  • Kurt R. Brekke
  • Dag Morten Dalen
  • Odd Rune Straume
Journal of Health Economics (2023) 90: 102778.
Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?
  • Sabine Vogler
  • Maximilian Salcher-Konrad
  • Katharina Habimana
Expert Review of Pharmacoeconomics & Outcomes Research (2023) 23 (8): 867.
Inflation, Price Controls and Compliance during the Korean War
  • Vincent Carret
SSRN Electronic Journal (2023)
Reference Pricing as a Deterrent to Entry: Evidence from the European Pharmaceutical Market
  • Luca Maini
  • Fabio Pammolli
American Economic Journal: Microeconomics (2023) 15 (2): 345.
Regulatory Environment and Approvals in Cell and Gene Therapy Products Between Japan, the USA, and the EU
  • Yuya Sato
  • Shunsuke Ono
Therapeutic Innovation & Regulatory Science (2023) 57 (2): 227.
What condition leads to an unreasonable pharmaceutical price? Impact research on the effect of medical service provision on pharmaceutical price regulation based on fuss-set QCA
  • Lingzhi Brian Fang
  • Xinmeng Wang
  • Liu Tang
  • Xingwei Li
PLOS ONE (2023) 18 (4): e0284129.
Accelerating Innovation Ecosystems: The Promise and Challenges of Regional Innovation Engines
  • Jorge Guzman
  • Fiona E. Murray
  • Scott Stern
  • Heidi Williams
SSRN Electronic Journal (2023)
Profiting from Most-Favored-Customer Procurement Rules: Evidence from Medicaid
  • Josh Feng
  • Thomas Hwang
  • Luca Maini
American Economic Journal: Economic Policy (2023) 15 (2): 166.
Rent Control, Market Segmentation, and Misallocation: Causal Evidence from a Large-Scale Policy Intervention
  • Andreas Mense
  • Claus Michelsen
  • Konstantin A. Kholodilin
Journal of Urban Economics (2023) 134: 103513.
Pharmaceutical regulation under market integration through parallel trade
  • Laura Birg
Canadian Journal of Economics/Revue canadienne d'économique (2023) 56 (4): 1322.
International reference pricing of pharmaceuticals in the United States: Implications for potentially curative treatments
  • Sean D Sullivan
  • Kiera D Sullivan
  • Omar Dabbous
  • Louis P Garrison
Journal of Managed Care & Specialty Pharmacy (2022) 28 (5): 566.
Financing Biomedical Innovation
  • Andrew W. Lo
  • Richard T. Thakor
Annual Review of Financial Economics (2022) 14 (1): 231.
Incentives for pharmaceutical innovation: What’s working, what’s lacking
  • Margaret K. Kyle
International Journal of Industrial Organization (2022) 84: 102850.
Pharmaceutical spending and early-stage innovation in EU countries
  • Dimitrios Kourouklis
  • Afschin Gandjour
Industry and Innovation (2022) 29 (10): 1141.
The effect of patented drug price on the share of new medicines across OECD countries
  • Oliver Spicer
  • Paul Grootendorst
Health Policy (2022) 126 (8): 795.
Policy uncertainty and behavior of foreign firms in emerging economies
  • Amit Karna
  • Shamim S. Mondal
  • Viswanath Pingali
Management Decision (2022) 60 (8): 2294.
Direct and indirect savings from parallel imports in Sweden
  • David Granlund
Health Economics Review (2022) 12 (1)
The same old medicine but cheaper: The impact of patent expiry on physicians’ prescribing behaviour
  • Gianluca Fiorentini
  • Matteo Lippi Bruni
  • Irene Mammi
Journal of Economic Behavior & Organization (2022) 204: 37.
A Toolkit for Setting and Evaluating Price Floors
  • Santiago Cantillo Cleves
  • Carlos Eduardo Hernandez
SSRN Electronic Journal (2022)
Balancing WTO-TRIPS Standard Against Nigeria Counterfeit Regulatory Efforts
  • Ifueko Itohan Imasuen
  • Augustine O. Nwajana
International Journal of Public and Private Perspectives on Healthcare, Culture, and the Environment (2022) 6 (1): 1.
Which policies for vaccine innovation and delivery in Europe?
  • Mathias Dewatripont
International Journal of Industrial Organization (2022) 84: 102858.
Product patents and access to innovative medicines
  • Rong Dai
  • Jayashree Watal
Social Science & Medicine (2021) 291: 114479.
Differential diffusion of pharmaceutical innovations in a mixed market middle - income economy
  • Nurhafiza Md Hamzah
  • Kok Fong See
BMC Health Services Research (2021) 21 (1)
INNOVATION AND DIFFUSION OF MEDICAL TREATMENT
  • Barton H. Hamilton
  • Andrés Hincapié
  • Robert A. Miller
  • Nicholas W. Papageorge
International Economic Review (2021) 62 (3): 953.
Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment
  • Mujaheed Shaikh
  • Pietro Del Giudice
  • Dimitrios Kourouklis
Applied Health Economics and Health Policy (2021) 19 (2): 217.
Rare Diseases Require Support Too
  • Viswanath Pingali
  • Neelima Das
Vikalpa: The Journal for Decision Makers (2021) 46 (2): 129.
How Does Regulation Impact Strategic Repositioning by Firms Across Submarkets? Evidence from the Indian Pharmaceutical Industry
  • Ajay Bhaskarabhatla
  • Priyatam Anurag
  • Chirantan Chatterjee
  • Enrico Pennings
Strategy Science (2021) 6 (3): 209.
Targeted Price Controls on Supermarket Products
  • Diego Aparicio
  • Alberto Cavallo
The Review of Economics and Statistics (2021) 103 (1): 60.
Can we achieve affordable cancer medicine prices? Developing a pathway for change
  • Sabine Vogler
Expert Review of Pharmacoeconomics & Outcomes Research (2021) 21 (3): 321.
Killer Acquisitions
  • Colleen Cunningham
  • Florian Ederer
  • Song Ma
Journal of Political Economy (2021) 129 (3): 649.
Stakeholder Orientation and Market Impact: Evidence from India
  • Arzi Adbi
  • Ajay Bhaskarabhatla
  • Chirantan Chatterjee
Journal of Business Ethics (2020) 161 (2): 479.
Optimal price regulations in international pharmaceutical markets with generic competition
  • Difei Geng
  • Kamal Saggi
Journal of Health Economics (2020) 71: 102315.
Impact of changes in the methodology of external price referencing on medicine prices: discrete-event simulation
  • Sabine Vogler
  • Peter Schneider
  • Lena Lepuschütz
Cost Effectiveness and Resource Allocation (2020) 18 (1)
Why healthcare market needs government intervention to improve access to essential medicines and healthcare efficiency: a scoping review from pharmaceutical price regulation perspective
  • Mende Mensa Sorato
  • Majid Davari
  • Akbar Abdollahi Asl
  • Fatemeh Soleymani
  • Abbas Kebriaeezadeh
Journal of Pharmaceutical Health Services Research (2020) 11 (4): 321.
Launch of a product and patents: evidence from the US cardiovascular pharmaceutical sector
  • F. Di Iorio
  • M. Letizia Giorgetti
Industry and Innovation (2020) 27 (7): 789.
A Comparative Study of the Market Configuration of the Japanese Pharmaceutical Market Using the Gini Coefficient and Herfindahl–Hirschman Index
  • Shoyo Shibata
  • Daigo Fukumoto
  • Takeshi Suzuki
  • Koken Ozaki
Therapeutic Innovation & Regulatory Science (2020) 54 (5): 1047.
The ACA Medicaid Rebate Rule Change: Impact on Pricing and Innovation
  • Josh Feng
  • Thomas Hwang
  • Luca Maini
SSRN Electronic Journal (2020)
Innovation for and from emerging countries: a closer look at the antecedents of trickle-down and reverse innovation
  • Verdiana Giannetti
  • Gaia Rubera
Journal of the Academy of Marketing Science (2020) 48 (5): 987.
Regulating Innovation with Uncertain Quality: Information, Risk, and Access in Medical Devices
  • Matthew Grennan
  • Robert J. Town
American Economic Review (2020) 110 (1): 120.
On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector
  • Pierre Dubois
  • Morten Sæthre
Econometrica (2020) 88 (6): 2503.
Umbrella branding in pharmaceutical markets
  • Moritz Suppliet
Journal of Health Economics (2020) 73: 102324.
How to address medicines shortages: Findings from a cross-sectional study of 24 countries
  • Sabine Vogler
  • Stefan Fischer
Health Policy (2020) 124 (12): 1287.
Effectiveness of National Pricing Policies for Patent-Protected Pharmaceuticals in the OECD: A Systematic Literature Review
  • Dominik J. Wettstein
  • Stefan Boes
Applied Health Economics and Health Policy (2019) 17 (2): 143.
Price Caps versus Reimbursement Limits: Pharmaceutical Regulation under Market Integration through Parallel Trade
  • Laura Birg
SSRN Electronic Journal (2019)
The Single Market in Pharmaceuticals
  • Margaret K. Kyle
Review of Industrial Organization (2019) 55 (1): 111.
Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing
  • Sabine Vogler
  • Peter Schneider
  • Nina Zimmermann
PharmacoEconomics - Open (2019) 3 (3): 303.
Price Controls in Liberia
  • John Spray
  • Eric Werker
Economic Development and Cultural Change (2019) 67 (3): 461.
Fair prices for medicines? Exploring competent authorities’ and public payers’ preferences on pharmaceutical policies
  • Sabine Vogler
Empirica (2019) 46 (3): 443.
Comparing approval procedures for new drugs
  • Nicolas Houy
  • Izabela Jelovac
The World Economy (2019) 42 (5): 1598.

Advertisement

  • Online ISSN 1530-9142
  • Print ISSN 0034-6535
A product of The MIT Press
Newsletter Sign Up

MIT Press Direct

Information

MIT Press

Contact Us

© 2023 The MIT Press
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. No content on this site may be used to train artificial intelligence systems without permission in writing from the MIT Press.
Accept